1 recruiting. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Recruiting 1 |
Follow Martin Huelsmann: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients RAS-antagonist and beta-blocker up-to maximal dosages, RAS-antagonist and beta-blocker none or at stable dose - Heart Diseases, Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | Martin Huelsmann | 2400 | 2016-02-01 | 2023-03-14 |
Diabetes Mellitus, Type 2 (1) · Heart Diseases (1)
Bisoprolol (1) · Captopril (1) · Carvedilol (1) · Cilazapril (1) · Enalapril (1) · Fosinopril (1) · Irbesartan (1) · Lisinopril (1) · Losartan (1) · Nebivolol (1) · Perindopril (1) · Quinapril (1) · Ramipril (1) · Valsartan (1) · candesartan (1)
Austria (1) · Netherlands (1) · New Zealand (1) · Spain (1) · United Kingdom (1)